Drug intelligence / Profile preview

ExoBall

Development stage: Preclinical
Lead developer: EVMed
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

ExoBall is a proprietary exosome-based product developed by EVMed Group, featuring a specialized "ball" formulation. It is designed for both therapeutic and diagnostic applications, leveraging the natural delivery and signaling capabilities of extracellular vesicles (EVs). As part of EVMed's exosome technology platform—which includes isolation and characterization tools like ExoPlus, ExoCell, and ExoPure—ExoBall represents a unique format for the delivery of bioactive molecules or for use as a diagnostic substrate. While the product is categorized under EVMed's prescription product line, specific molecular targets, pharmacological mechanisms, and clinical indications remain proprietary or are in early-stage development.

Brand names: ExoBall
Other names: ExoBall™

Beyond the preview

Go deeper on ExoBall.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoBall.

Explore the full profile